Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Product approval in US

7 Feb 2008 07:00

ViaLogy PLC07 February 2008 VIALOGY SPM product successfully tested and approved by US National Incident Management System London, 7 February, 2008: ViaLogy PLC (LSE: VIY), a leading innovator ofreal-time network-centric signal processing platforms, announces that itsproduct SPMTM (Sensor Policy ManagerTM), for sensor interoperability andintegration, has received unqualified approval from America's National IncidentManagement System Support Center (NIMS SC), a division of The Department ofHomeland Security's (DHS) Federal Emergency Management Agency (FEMA). NIMSawarded SPM top marks in all tested categories. NIMS has been established by the US government to deal with national emergencysituations, including terrorist attacks. It enables responders from differentjurisdictions and disciplines to work together to respond to natural disastersand emergencies, including acts of terrorism. Benefits include a unifiedapproach to incident management; standard command and management structures; andemphasis on preparedness, mutual aid and resource management. Key to any emergency situation response is the ability of all the differentsensors involved to integrate information and prioritise alerts. ViaLogy's SPMis designed specifically to enable this to happen seamlessly and immediately. Inrecent weeks NIMS engineers have been subjecting the product to extensive andrigorous testing. They have determined that SPM meets all its requiredstandards. "The product is consistent with the concepts and principles of NIMS,"concludes the Evaluation Report. "It is applicable to all 15 Emergency SupportFunctions, all six hazard groups, and to a multi-jurisdictional response." Ineach case the tests marked SPM five out of five. In addition, the report praisedthe speed at which SPM could be incorporated in any sensor and the fact that ittakes just 20 hours to fully train an SPM operator. "We are absolutely delighted with the NIMS validation," said Robert W. Dean,President and CEO of ViaLogy. "Our SPM product is designed to enable aco-ordinated proactive response by all the emergency services involved indealing with an emergency incident. Quite simply, it will help to save lives. "Most importantly, the system is sensor agnostic so it can create instantcommunication between a wide variety of sensors used in a range of safety,security and emergency response applications." ViaLogy is also participating in additional validation demonstrations with anumber of manufacturers involved in producing and integrating commercialsecurity systems. ends ViaLogyRobert W Dean, President/CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)Terry Bond, Chairman - UK & Europe +44 (0)1235 834734 Nominated Advisor (Seymour Pierce)Mark Percy +44 (0)20 7107 8000 PR Consultants - Redleaf CommunicationsEmma Kane / Samantha Robbins +44 (0)20 7822 0200 About ViaLogy: Network Centric Signal Processing. ViaLogy is a leading innovator of network-centric, real-time signal processingplatforms for sensor applications and sensor fusion. ViaLogy is currentlydeploying and designing computational systems, powered by its patentedtechnologies, for applications in life sciences, public safety and security,surveillance, defense and geoseismology. Vialogy focuses on market drivenproblems where automation, timeliness, quality and reliability of informationprocessing are essential. ViaLogy's core competency incorporates rapidly andaccurately detecting weak signals buried in high noise background and clutter.This technology can be employed to solve problems involving sensor integrationand information overload challenges involving video, telephony and controlsensors, as well as for enhancement of numerous signal processing applications.For more information, visit our website at www.vialogy.com. Except for statements of historical fact, the information presented hereinconstitutes forward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such forward-looking statementsinvolve known and unknown risks, uncertainties and other factors which may causethe actual results, performance or achievements of the company to be materiallydifferent from any future results, performance or achievements expressed orimplied. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th Jan 20237:00 amRNSDirectorate Change
18th Jan 202312:07 pmRNSDirector/PDMR Shareholding
17th Jan 202312:06 pmRNSHolding(s) in Company
13th Jan 20234:27 pmRNSDirector/PDMR Shareholding
13th Jan 20231:03 pmRNSHolding(s) in Company
12th Jan 20233:48 pmRNSHolding(s) in Company
12th Jan 20232:43 pmRNSHolding(s) in Company
11th Jan 202312:23 pmRNSHolding(s) in Company
11th Jan 202311:29 amRNSHolding(s) in Company
11th Jan 202311:26 amRNSDirector/PDMR Shareholding
9th Jan 20235:25 pmRNSResult of General Meeting and Retail Offer
6th Jan 20234:35 pmRNSClose of Retail Offer
6th Jan 20233:34 pmRNSHolding(s) in Company
29th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20221:09 pmRNSDirector/PDMR Shareholding
23rd Dec 202211:29 amRNSHolding(s) in Company
23rd Dec 20227:00 amRNSPosting of Circular and Notice of General Meeting
22nd Dec 202211:00 amRNSRetail Offer
22nd Dec 20227:00 amRNSResult of Placing and Subscriptions
21st Dec 20222:29 pmRNSProposed Capital Raising
21st Dec 20222:25 pmRNSHalf-year Report
25th Nov 202211:00 amRNSPrice Monitoring Extension
3rd Nov 20227:00 amRNSFirst half trading update
27th Sep 20223:08 pmRNSResult of AGM
27th Sep 20227:00 amRNSAGM Statement
25th Aug 20227:00 amRNSNotice of AGM & Change of Registered Address
16th Aug 20227:00 amRNSOpen Day and advance notice of AGM
27th Jul 20227:00 amRNSAudited Final Results
27th Jul 20227:00 amRNSDr John Brown CBE confirmed as Chairman
11th Jul 20227:00 amRNSNotice of Final Results
24th May 20227:00 amRNSAccelerator Phase Launch for Microdeletions Plugin
12th May 202211:06 amRNSSecond Price Monitoring Extn
12th May 202211:00 amRNSPrice Monitoring Extension
12th May 20227:00 amRNSCEO share purchase
26th Apr 20227:01 amRNSDirectorate Change
26th Apr 20227:00 amRNSFull year trading update
25th Apr 20227:00 amRNSStrategic partnership extended with Ambry Genetics
12th Apr 20227:00 amRNSIssue of share options and total voting rights
6th Apr 20227:00 amRNSCapital Markets Day
21st Mar 20224:23 pmRNSDirector/PDMR Shareholding
17th Feb 20227:00 amRNSSuccessful CTDA desktop review
25th Jan 20227:00 amRNSDirectorate Change
24th Jan 20227:00 amRNSDirector Dealing
21st Jan 20222:48 pmRNSIssue of Equity & Total Voting Rights
19th Jan 20227:00 amRNSOpening of new Yourgene Health Canada facilities
19th Jan 20227:00 amRNSAgreement of new debt facility
18th Jan 20227:00 amRNSUS partnership with EKF for NIPT and genomic tests
17th Jan 20227:00 amRNSCurrent year trading update
23rd Dec 20217:00 amRNSDHSC contract award for COVID Winter surge testing
14th Dec 202111:00 amRNSUKHSA contract award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.